TB-500 vs Thymosin β-4.

TB-500 is a synthetic peptide sold for research use and widely marketed as "thymosin beta-4 (Tβ4)." Naturally occurring Tβ4 is a 43-amino-acid, ~4.9 kDa actin-sequestering peptide found in nearly all mammalian cells and at high concentration in platelets and wound fluid. Notably, many products labeled "TB-500" are actually a shorter synthetic fragment built around the active actin-binding motif (LKKTET/LKKTETQ) rather than the full-length Tβ4 molecule, so the name is used loosely in the research-chemical market and the exact identity of a given vial is often unverified.

Thymosin beta-4 (Tβ4) is a small, naturally occurring 43-amino-acid acidic peptide found in nearly all mammalian cells and in high concentrations in platelets, wound fluid, and many tissues. It is the principal member of the beta-thymosin family and is one of the most abundant actin-binding proteins in the cytoplasm. The injectable "research peptide" TB-500 is widely marketed as thymosin beta-4, but it is typically a synthetic fragment or analog of the parent molecule rather than the full-length, naturally sequenced peptide; the two are not strictly interchangeable.

The best-characterized function of thymosin beta-4 is binding monomeric G-actin in a 1:1 complex, acting as the principal intracellular actin-sequestering peptide that buffers the pool of unpolymerized actin and thereby modulates cytoskeletal assembly, cell shape, and migration. Through the LKKTET motif and downstream signaling, Tβ4 has been reported in preclinical models to promote keratinocyte and endothelial cell migration, angiogenesis, anti-inflammatory and anti-apoptotic effects, and activation of integrin-linked kinase (ILK)/Akt and laminin-5 pathways relevant to wound repair. These mechanisms are mostly established in cell and animal systems; the degree to which a synthetic LKKTET-type fragment reproduces full-length Tβ4 biology is not firmly established.

Tβ4's best-characterized molecular function is sequestering monomeric (G-)actin: it binds G-actin in a roughly 1:1 ratio, buffers the pool of unpolymerized actin, and thereby regulates cytoskeletal assembly, cell migration, and motility. Beyond this structural role, Tβ4 has been reported to upregulate cell-survival signaling, notably activation of integrin-linked kinase (ILK) and the Akt pathway in cardiac cells, and to influence angiogenesis, inflammation, and the actin-binding protein laminin/myosin machinery during tissue remodeling. It also has downstream effects attributed to its N-terminal tetrapeptide (Ac-SDKP), a cleavage product with antifibrotic and anti-inflammatory activity. These mechanisms are largely defined in cell-culture and animal systems.

Human evidence comes almost entirely from the full-length Tβ4 molecule developed pharmaceutically by RegeneRx and partners, not from research-chemical "TB-500." Topical Tβ4 (RGN-137) was tested in completed Phase 2 dermal-wound trials including a randomized, placebo-controlled study in venous stasis ulcers (ClinicalTrials.gov NCT00832091), and ophthalmic Tβ4 (RGN-259) has advanced to Phase 3 for neurotrophic keratopathy (e.g., the SEER-2 trial, NCT05555589). Preclinical support for dermal, corneal, and cardiac repair is substantial and replicated across labs, as reviewed by Kleinman and Sosne (Vitamins and Hormones, 2016). However, there are no controlled human trials of injectable "TB-500" as sold in the peptide market for musculoskeletal healing, tendon/ligament injury, or athletic recovery; those uses rest on animal data and extrapolation, and the human-vs-preclinical gap is wide.

The strongest human clinical data come from ophthalmology: the full-length peptide as RGN-259 (0.1% Tβ4 ophthalmic solution, RegeneRx/regional partners) was studied in a randomized, placebo-controlled, double-masked Phase III trial in neurotrophic keratopathy (Int J Mol Sci 2022, PMID 36613994), and in the ARISE-1/-2/-3 Phase III dry-eye program, where ARISE-3 missed its co-primary endpoints but showed significant improvement in some pre-specified secondary sign/symptom measures with a clean safety profile. Most other applications remain preclinical: the landmark cardiac work (Bock-Marquette et al., Nature 2004, PMID 15565145) showed Tβ4 promoted cardiomyocyte migration, survival, and improved cardiac function after injury in mice via ILK/Akt, and dermal/corneal wound-healing benefits are documented in animal models (e.g., Sosne et al., Exp Eye Res 2002, PMID 11950239). There is no FDA-approved Tβ4 product and no robust human evidence for the systemic "tissue repair," tendon/muscle recovery, or anti-aging uses for which TB-500 is informally promoted; that gap between animal data and proven human benefit is substantial.

There is no established human safety profile for research-chemical "TB-500"; it is not a licensed drug and is not manufactured to pharmaceutical quality, so identity, purity, sterility, and endotoxin content of marketed vials are unverified. Pharmaceutical full-length Tβ4 has been reasonably well tolerated in controlled topical and ophthalmic trials, but those findings do not transfer to unregulated injectable products. A recurring theoretical concern is that a peptide promoting angiogenesis and cell migration could be undesirable in the setting of occult malignancy, though this is not established as a clinical harm. Contamination, dosing errors, and injection-related risks are the most concrete real-world hazards.

In the controlled ophthalmic trials, topical Tβ4 (RGN-259) was generally well tolerated with a safety profile comparable to placebo, but those data are limited to eye-drop administration and do not establish the safety of systemic injection. For injectable TB-500 sold as a research chemical, there are essentially no published controlled human safety data: long-term effects, immunogenicity, and risks are not characterized in humans. A specific theoretical concern is Tβ4's role in cell migration and angiogenesis, which has prompted caution about effects on tumor growth or metastasis; some preclinical studies link elevated Tβ4 to more aggressive tumor behavior. Material sold outside regulated channels also carries contamination, mislabeling, and dosing-uncertainty risks. No doses or protocols are provided here.

TB-500/thymosin beta-4 is not approved by the FDA or EMA for any indication; full-length Tβ4 remains investigational (RegeneRx/ReGenTree ophthalmic and dermal programs), and material sold as "TB-500" is research-use-only and not a dietary supplement or medicine. It is prohibited in sport at all times by the World Anti-Doping Agency under class S2 (peptide hormones, growth factors, related substances and mimetics).

Thymosin beta-4 is not FDA-approved for any indication; the full-length peptide (RGN-259) is investigational, completed Phase III trials in eye disease, and has held orphan-drug designation but no marketing approval, while injectable TB-500 is sold only as a research-use/unapproved compound. It is prohibited in sport at all times by WADA under section S2 (peptide hormones, growth factors, related substances and mimetics).